In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finding The Fit For Ophthalmology In The New Pfizer

Executive Summary

The merger of Pfizer and Allergan might raise broader questions about the fairness – or long-term viability – of the corporate tax code in the US. But it also has generated some angst over Allergan’s future as a stalwart in ophthalmology.

You may also be interested in...



M&A Deals Drop In 2015, With IVD-Sector Transactions Still Leading The Pack

There were 225 medtech M&A deals in 2015, down from 269 in 2014, according to Clinica's M&A Tracker. The in vitro diagnostics sector continues to be the most popular for transactions.

Pfizer/Allergan: Breaking Up Is Hard To Do (Unless There’s A New Tax Law)

The breakup fee for the Pfizer/Allergan merger would be $3.5bn in certain instances, but much lower, just $400m in expense reimbursement, if a party decides to terminate the deal due to an adverse change in law.

Ophthalmology Surgeons, Companies Finding Solutions In Medtech

Minimally invasive technologies are finding their way into the suites of ophthalmology surgeons. Just over the past six months, Allergan has acquired two pre-commercial medtech companies developing miniature implants to treat glaucoma and dry eye disease. Meanwhile, Glaukos, a leader in the micro-invasive glaucoma surgery market, remains one of the more successful medtech IPOs.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel